Cover Image
Market Research Report

Asia Pacific Opioids Drug Market Forecast 2019-2027

Published by Inkwood Research Product code 757036
Published Content info 77 Pages
Delivery time: 1-2 business days
Price
Back to Top
Asia Pacific Opioids Drug Market Forecast 2019-2027
Published: December 17, 2018 Content info: 77 Pages
Description

KEY FINDINGS

The regional market for opioid drugs in the Asia-Pacific is rapidly growing at 3.06% CAGR during the forecast period 2019-2027, where it was valued $XX million in its base year of 2018. The rising awareness about palliative care that is necessary for patients suffering from incurable diseases is expected to drive the market growth in this region. China, India, Japan, Australia, South Korea & Rest of Asia Pacific are deliberated for this study.

MARKET INSIGHTS

The sale of sustained-release formulations of opioid drugs and other forms of opioid-dependent pain relief medications are expected to pave more ways for the market growth. Also, the reduction in the use of non-addictive pain relievers is going to enhance the use of addiction-deterrent variants of opioid drugs in the upcoming years. Japan owns the largest shares of the Asia Pacific opioid drugs market, mainly because of the higher frequency of chronic and severe pain, although the market growth can get obstructed due to the strict and restrictive laws for its prescriptions and the stigma associated with opioid addiction.

COMPETITIVE INSIGHTS

Hikma Pharmaceuticals PLC, Acura Pharmaceuticals, Inc., Lannett Co. Inc., BioDelivery Sciences International, Inc., Sun Pharmaceutical Industries Limited (Sun Pharma), Cipher Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc., Daiichi Sankyo, Inc., Allergan PLC, Egalet Corp., Indivior, Inc., Insys Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Lupin Ltd., Mylan NV, Pfizer, Inc., Purdue Pharma LP, Sanofi-Aventis S.A. and Teva Pharmaceutical Industries Ltd. are the predominant revenue reapers for the Asia-Pacific opioid drugs market.

Table of Contents
Product Code: 22725

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. OXYCODONE HOLDS THE LARGEST MARKET SHARE IN TERMS OF PRODUCT
    • 3.2.2. ANESTHESIA IS THE MAJORLY USED APPLICATION

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. INCREASING ROAD ACCIDENTS AND SURGICAL PROCEDURES
    • 4.2.2. ESCALATING PALLIATIVE CARE FOR PATIENTS SUFFERING INTENSELY
    • 4.2.3. USAGE OF ABUSE DETERRENT FORMULATIONS TO RESTRICT THE OPIOID ABUSE
    • 4.2.4. GROWING OCCURRENCE OF CHRONIC PAIN
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. MISUSE OF OPIOIDS
    • 4.3.2. STRINGENT REGULATORY FRAMEWORK
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. INCREASING USE OF EXTENDED-RELEASE OPIOID FORMULATIONS
    • 4.4.2. WIDE RANGE OF APPLICATIONS OF OPIOIDS IN THE THERAPEUTIC MANAGEMENT
  • 4.5. MARKET CHALLENGES
    • 4.5.1. INCREASING NUMBER OF LAWSUITS AGAINST OPIOIDS MANUFACTURERS
    • 4.5.2. RISING OCCURRENCE OF DEATHS RELATED TO OPIOID OVERDOSE

5. MARKET BY PRODUCTS

  • 5.1. BUPRENORPHINE
  • 5.2. FENTANYL
  • 5.3. HYDROCODONE
  • 5.4. MORPHINE
  • 5.5. OXYCODONE
  • 5.6. TRAMADOL
  • 5.7. OTHER PRODUCTS

6. MARKET BY APPLICATION

  • 6.1. PAIN RELIEF
    • 6.1.1. CANCER PAIN
    • 6.1.2. POSTOPERATIVE PAIN MANAGEMENT
    • 6.1.3. LOW BACK PAIN
    • 6.1.4. ORTHOPEDIC
    • 6.1.5. NEUROPATHIC
    • 6.1.6. FIBROMYALGIA
  • 6.2. ANESTHESIA
  • 6.3. COUGH SUPPRESSION
  • 6.4. DIARRHEA SUPPRESSION
  • 6.5. DEADDICTION

7. KEY ANALYTICS

  • 7.1. PORTER'S FIVE FORCE MODEL
    • 7.1.1. THREAT OF NEW ENTRANTS
    • 7.1.2. THREAT OF SUBSTITUTE
    • 7.1.3. BARGAINING POWER OF SUPPLIERS
    • 7.1.4. BARGAINING POWER OF BUYERS
    • 7.1.5. THREAT OF COMPETITIVE RIVALRY
  • 7.2. PIPELINE ANALYSIS
  • 7.3. INDUSTRY EVENTS IN OPIOID DRUGS MARKET
  • 7.4. TECHNOLOGIES ADVANCEMENT
  • 7.5. OPPORTUNITY MATRIX

8. GEOGRAPHICAL ANALYSIS

  • 8.1. ASIA PACIFIC
    • 8.1.1. JAPAN
    • 8.1.2. CHINA
    • 8.1.3. INDIA
    • 8.1.4. AUSTRALIA
    • 8.1.5. SOUTH KOREA
    • 8.1.6. REST OF ASIA PACIFIC

9. COMPETITIVE LANDSCAPE

  • 9.1. MARKET POSITION ANALYSIS
  • 9.2. COMPANY PROFILES
    • 9.2.1. ACURA PHARMACEUTICALS, INC.
    • 9.2.2. ALLERGAN PLC
    • 9.2.3. BIODELIVERY SCIENCES INTERNATIONAL, INC.
    • 9.2.4. CIPHER PHARMACEUTICALS INC.
    • 9.2.5. COLLEGIUM PHARMACEUTICAL, INC.
    • 9.2.6. DAIICHI SANKYO, INC.
    • 9.2.7. EGALET CORP.
    • 9.2.8. HIKMA PHARMACEUTICALS PLC
    • 9.2.9. INDIVIOR INC.
    • 9.2.10. INSYS THERAPEUTICS, INC.
    • 9.2.11. JANSSEN PHARMACEUTICALS, INC.
    • 9.2.12. JOHNSON & JOHNSON
    • 9.2.13. LANNETT CO. INC.
    • 9.2.14. LUPIN LTD.
    • 9.2.15. MYLAN NV
    • 9.2.16. PFIZER INC.
    • 9.2.17. PURDUE PHARMA LP
    • 9.2.18. SANOFI-AVENTIS S.A.
    • 9.2.19. SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)
    • 9.2.20. TEVA PHARMACEUTICAL INDUSTRIES LTD.

LIST OF TABLES

  • TABLE 1 ASIA PACIFIC OPIOIDS DRUG MARKET 2019-2027 ($ MILLION)
  • TABLE 2 ANESTHETIC EFFECTS OF DRUGS AT DIFFERENT OPIOID RECEPTORS
  • TABLE 3 NUMBER OF LAWSUITS SETTLED BY OPIOIDS MANUFACTURING COMPANIES AND PHARMACIES 2015-2027
  • TABLE 4 ASIA PACIFIC OPIOIDS DRUGS MARKET BY PRODUCTS 2019-2027 ($ MILLION)
  • TABLE 5 ASIA PACIFIC BUPRENORPHINE MARKET 2019-2027 ($ MILLION)
  • TABLE 6 ASIA PACIFIC FENTANYL MARKET 2019-2027 ($ MILLION)
  • TABLE 7 ASIA PACIFIC HYDROCODONE MARKET 2019-2027 ($ MILLION)
  • TABLE 8 ASIA PACIFIC MORPHINE MARKET 2019-2027 ($ MILLION)
  • TABLE 9 ASIA PACIFIC OXYCODONE MARKET 2019-2027 ($ MILLION)
  • TABLE 10 ASIA PACIFIC TRAMADOL MARKET 2019-2027 ($ MILLION)
  • TABLE 11 ASIA PACIFIC OTHER PRODUCTS MARKET 2019-2027 ($ MILLION)
  • TABLE 12 ASIA PACIFIC OPIOIDS DRUGS MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 13 ASIA PACIFIC OPIOIDS DRUGS MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 14 ASIA PACIFIC PAIN RELIEF MARKET 2019-2027 ($ MILLION)
  • TABLE 15 ASIA PACIFIC PAIN RELIEF MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 16 ASIA PACIFIC CANCER PAIN MARKET 2019-2027 ($ MILLION)
  • TABLE 17 ASIA PACIFIC POSTOPERATIVE PAIN MANAGEMENT MARKET 2019-2027 ($ MILLION)
  • TABLE 18 ASIA PACIFIC LOW BACK PAIN MARKET 2019-2027 ($ MILLION)
  • TABLE 19 ASIA PACIFIC ORTHOPEDIC MARKET 2019-2027 ($ MILLION)
  • TABLE 20 ASIA PACIFIC NEUROPATHIC MARKET 2019-2027 ($ MILLION)
  • TABLE 21 ASIA PACIFIC FIBROMYALGIA MARKET 2019-2027 ($ MILLION)
  • TABLE 22 ASIA PACIFIC ANESTHESIA MARKET 2019-2027 ($ MILLION)
  • TABLE 23 ASIA PACIFIC COUGH SUPPRESSION MARKET 2019-2027 ($ MILLION)
  • TABLE 24 ASIA PACIFIC DIARRHEA SUPPRESSION MARKET 2019-2027 ($ MILLION)
  • TABLE 25 ASIA PACIFIC DEADDICTION MARKET 2019-2027 ($ MILLION)
  • TABLE 26 PIPELINE ANALYSES OF OPIOID DRUGS
  • TABLE 27 ASIA PACIFIC GERD DRUGS AND DEVICES MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC OPIOIDS DRUG MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 ASIA PACIFIC OPIOIDS DRUGS MARKET SHARE BY PRODUCTS 2018 & 2027 (%)
  • FIGURE 3 ASIA PACIFIC OPIOIDS DRUGS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 4 PORTER'S FIVE FORCE MODEL
  • FIGURE 5 ASIA PACIFIC OPIOIDS DRUGS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 6 JAPAN GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 7 CHINA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 8 INDIA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
  • FIGURE 9 AUSTRALIA OPIOIDS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 10 SOUTH KOREA OPIOIDS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 11 REST OF ASIA PACIFIC OPIOIDS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 12 OPIOIDS MARKET POSITION ANALYSIS 2017
Back to Top